Skip to main content

Table 1 Baseline population characteristics according to arm of treatment

From: Efficacy of Helicobacter pylori eradication regimens in Rwanda: a randomized controlled trial

Characteristics Total (n = 229) CLARITHRO
n = 6127%
CIPRO
n = 5624%
METRO
n = 5725%
CIPRO-Plus
n = 5524%
Demographic characteristics Male (%) 35 43 43 35 35
Age, years mean ± SD 42 ± 16 40 ± 15 44 ± 16 41 ± 16 41 ± 17
Married (%) 57 52 68 60 49
CommunityHealth Insurance (%) 88 85 88 93 87
Access to endoscopy (days) 2.2 ± 3.1 1.9 ± 0.6 2.8 ± 6 2.3 ± 1.7 1.9 ± 0.6
Medical history PPI or H2 blocker before (%) 77 74 79 79 78
Triple therapy before (%) 17 13 23 16 18
Antibiotics before (%) 14 13 13 13 18
Symptoms Epigastric pain (%) 96 97 95 95 96
Vomiting (%) 30 27 38 19 35
Hematemesis (%) 8 10 9 4 9
Melena (%) 2 2 4 2 2
Endoscopy finding Normal endoscopy (%) 16 18 14 21 11
Gastritis (%) 56 41 55 61 67
Gastric ulcer (%) 11 10 14 14 7
Duodenal ulcer (%) 30 41 36 25 16
Initially positive FAT (%) 37 39 39 39 31
Baseline HRQoLtotal group(mean ± SD score) 76 ± 11 77 ± 13 76 ± 12 76 ± 8 78 ± 12
Baseline HRQoLin functional dyspepsia (n = 37) (mean ± SD score) 73 ± 12 71 ± 9 70 ± 17 74 ± 10 76 ± 14
  1. Baseline characteristics of the intention to treat population were not significantly different, except for gastritis (CIPRO Plus and METRO were significantly different from CLARITHRO, with p = 0.005 and p = 0.02, respectively) and for duodenal ulcer (CIPRO Plus was significantly different from CLARITHRO, p = 0.004).Abbreviations: SD Standard deviation, FAT Fecal Antigen Test, PP Proton Pump Inhibitors